1
CARDIOVASCULAR
hamburger

The CardioMEMS HF System provides the actionable data you need to empower intelligent remote monitoring.

Clinicians have traditionally relied on physical markers, such as weight, blood pressure and symptoms to manage the care of their heart failure patients. These lagging indicators give clinicians little time to respond before hospitalization of a patient becomes necessary.

The CardioMEMS™ HF System is a one-of-a-kind remote monitoring technology that detects changes in pulmonary artery (PA) pressure – an early indicator of worsening heart failure. This technology not only alerts you if a patient’s heart failure is worsening – but gives you the actionable data you to need to intervene before a patient feels symptoms.

Graphic showing transmission flow

Improving Patient Outcomes

Abbott’s CardioMEMS HF System is the only remote monitoring platform clinically proven to aid physicians in preventing worsening heart failure.

Reduction in Hospitalizations

Reduction in hospitalizations for both types of heart failure and the ONLY management tool proven for HFpEF patients:
60% reduction in HFpEF hospitalizations
57% reduction in heart failure hospitalizations
54% reduction in HFrEF hospitalizations

Staying Home—And Out Of The Hospital

As telemedicine becomes more common, the CardioMEMS™ HF System is a safe, reliable way to remotely monitor and manage heart failure. It gives you actionable data to make informed care decisions for each patient without needing to see them in clinic.

It’s the personalized approach your patients deserve. This technology helps keep patients out of the hospital and provides the opportunity for them to reconnect with their lives knowing you are monitoring their heart failure – through the CardioMEMS™ HF System.

Reductions in 30-day Readmissions*

78% heart failure specific, 58% all cause

* Medicare-eligible population

Reductions in Mortality

30% lower mortality rate

References

  1. Shavelle D, et al. Lower rates of heart failure and allcause hospitalizations during pulmonary artery pressureguided therapy for ambulatory heart failure: One year outcomes from the CardioMEMS Post-Approval Study. Circulation: Heart Failure. 2020; e006836
  2. Adamson, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. Circulation: Heart Failure. 2016;115.002600.
  3. Abraham J, et al. Association of ambulatory hemodynamic monitoring with clinical outcomes in a concurrent matched cohort analysis. JAMA Cardiology. 2019;4(6):556-563.

Indications, Safety & Warnings

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications and Usage: The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: Infection, Arrhythmias, Bleeding, Hematoma, Thrombus, Myocardial infarction, Transient ischemic attack, Stroke, Death, and Device embolization.

MAT-2007036 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.